Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

tigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design and statements regarding the potential benefits and potential development of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product candidates and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

ORCA™, Borealis-1™, Borealis-2™, Spruce™, Rainier™ and Pacific™, are registered trademarks of OncoGenex Pharmaceuticals, Inc.
ABRAXANE® is a registered trademark of Celgene Corporation
JEVTANA® is a registered trademark of sanofi-aventis
Zytiga® is a registered trademark of the Johnson & Johnson Corporation

 


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... British Columbia , May 26, 2015 /PRNewswire/ ... announced today that it has filed a provisional ... Trademark Office ("USPTO") relating to the treatment of ... natural cannabinoid compounds developed by InMed. ... Chief Scientific Officer, commented, "We are excited to ...
(Date:5/22/2015)... 22, 2015  Research and Benchmarking firm, Best ... Medical Affairs Roundtable on Thursday, May 28th ... roundtable to discuss "Medical Affairs, Role in Health ... Medical Affairs Consortium provides Medical Affairs leaders with ... challenges they face. The consortium has developed a ...
(Date:5/22/2015)... mayo de 2015 Dipexium Pharmaceuticals, ... farmacéutica de fase tardía centrada en el ... 0.8%), y colaboradores de investigación clínica, han ... el diseño innovador de los ensayos pivotales ... evalúan Locilex®, su nuevo péptido de antibiótico ...
Breaking Medicine Technology:InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 2InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 3Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6
(Date:5/25/2015)... According to the National Library of Medicine, one in ... eye disease. The National Library of Medicine also states that ... , a rare disorder that causes sporadic muscle behavior or ... two diseases are more than a statistic – they’re a ... with his new autobiography “ The Way I See ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in dentistry. ... professional women, boasting more than 700,000 members and over ... welcome Laquanis into this exceptional group of professional women,” ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 World Patent ... products, launches The Preventer, a home patent that aims ... of fire. , "House fires cost the United States ... Cooper, CEO and Creative Director of World Patent ... result from homes that have no alarmed protection. With ...
(Date:5/25/2015)... 25, 2015 24Hr HomeCare is proud ... Brenneman-Slay, Co-Founder & COO, and Ryan Iwamoto, Co-Founder & ... Of The Year® 2015 Awards in Greater Los Angeles. ... demonstrate excellence in innovation, financial performance, and a personal ... the core of the ongoing success of our organization,” ...
(Date:5/25/2015)... 25, 2015 Stanley Consultants ... for design of the wastewater treatment expansion ... received a National Recognition Award from the American Council ... ACEC – Iowa. Competitions held by the organization ... $50.2 million expansion is Iowa City’s largest public works ...
Breaking Medicine News(10 mins):Health News:Joseph K. Chan Finds Faith from Disability in New Autobiography 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3
... July 10 The American people continue to move to the pro-life ... Knights of Columbus and Marist Poll. , , The poll mirrored ... than as pro-choice, and that the vast majority of Americans favor restricting ... , 86% of Americans ...
... 10 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com ... A Vaccine of 2009 was delivered to India, by the ... India this year by the company. The first batch was ... are recommended to receive Hepatitis A vaccine, including people at ...
... kicking motion yields surprising clues as to why , FRIDAY, ... have different patterns of injuries, and now U.S. researchers think ... examine the kicking motion in male and female soccer players, ... finding that could help prevent injuries in the future. , ...
... America, Inc., a leading medical diagnostic instrument manufacturer ... of Jim Cusack as Director of Business Development ... of Marketing & Medical Affairs, Sysmex America. ... the company,s existing business partnerships and in identifying ...
... Surfers, cancer survivors and supporters will gather ... with a special purpose: to show their support for the fight ... they will place their surfboards in the sand, one-by-one, nose-to-tail, with ... The line will start at Scripps Pier and continue down La ...
... Boston University School of Medicine (BUSM) and collaborators have ... ,EUK-400 series, which could someday be used to prevent ... brains of radiological terrorism victims. The findings, which appear ... Biological Inorganic Chemistry , describe new agents which can ...
Cached Medicine News:Health News:New Poll Shows Americans Continuing to Move Toward Pro-Life Position on Abortion 2Health News:Hard To Treat Diseases (HTDS.PK) Completes India Order 2Health News:Hard To Treat Diseases (HTDS.PK) Completes India Order 3Health News:Soccer Injuries Differ by Gender 2Health News:Sysmex America Names Industry Veteran to Business Development Post 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 3Health News:New oral agents may prevent injury after radiation exposure 2
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
... water perfused manometric catheters for ... diagnostic tests. All Medtronic Water ... clear, medical grade PVC tubing. ... esophagus you will find a ...
Esophageal Stylet for LATITUDE® Air-Charged Catheter...
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Medicine Products: